OncoSec and Serametrix Collaborate on Skin Cancer Immune Therapies

OncoSec enters into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. The goal of this research is to identify biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments.